Platform
Home
Screener
Copilot
AskEdgar Studio
New
Back
Climb Bio, Inc.
CLYM · SEC Filings
website
28
Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflamma...
Price
11.01
Market Cap
646.71 M
Float
42.03 M
Country
US
Sector
Healthcare
Exchange
NASDAQ
Overview
Filings
Insights
Dilution
News
Transcripts
Search in Documents
Open in Studio
Studio
Login
Ask about CLYM
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
TYPE
HEADLINE
FILED AT
All
Chronological
Financials
Registrations
Prospectus
News
Proxies
Ownerships
Other
Climb Bio, Inc.
CLYM · SEC Filings
42.03 M
Float
11.01
Price
646.71 M
Market Cap
Financials
TYPE
HEADLINE
FILED AT
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 5, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 6, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 7, 2026
10-K
Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Mar 5, 2026
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 6, 2025
10-Q
Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Aug 12, 2025
News
TYPE
HEADLINE
FILED AT
8-K
Climb Bio Reports Third Quarter 2026 Financial Results and Business Updates
Nov 5, 2026
8-K
Climb Bio Presents Initial PrisMN Phase 2 Data for Budoprutug in pMN at ASN Kidney Week 2026
Oct 26, 2026
8-K
Climb Bio and Mabworks Announce Positive Phase 1 Data for CLYM116/MIL116 in IgA Nephropathy at ASN Kidney Week 2026
Oct 23, 2026
8-K
Climb Bio Announces Positive Phase 1 Data for CLYM116 in IgA Nephropathy
Sep 3, 2026
8-K
Climb Bio Announces First Patient Dosed in Phase 2 IgA Nephropathy Trial in China
Aug 14, 2026
8-K
Climb Bio Reports Second Quarter 2026 Financial Results and Business Updates
Aug 6, 2026
Prospectus
TYPE
HEADLINE
FILED AT
424B5
[No Baby Shelf]* June 2026 ATM | Offering amount: $100,000,000 | Bank: Jefferies LLC
Jun 12, 2026
424B3
SHARE RESALE REGISTRATION | Shares: 11,587,000
Jun 9, 2026
424B5
March 2025 ATM
Mar 25, 2025
424B3
Common Stock
Jul 23, 2024
424B4
OFFERING | Shares amount: 6,400,000 | Share price: $12.50 | Offering amount: $80,000,000.00
Aug 11, 2021
Registrations
TYPE
HEADLINE
FILED AT
Proxies
TYPE
HEADLINE
FILED AT
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 24, 2026
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 24, 2026
PRE 14A
Form PRE 14A - Other preliminary proxy statements
Apr 10, 2026
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
May 23, 2025
DEFA14A
Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 25, 2025
DEF 14A
Form DEF 14A - Other definitive proxy statements
Apr 25, 2025
Ownerships
TYPE
HEADLINE
FILED AT
Chronological
TYPE
HEADLINE
FILED AT
Other
TYPE
HEADLINE
FILED AT
EFFECT
Form EFFECT - Notice of Effectiveness
Jun 10, 2026
CORRESP
Form CORRESP - Correspondence
Jun 5, 2026
LETTER
Form UPLOAD - SEC-generated letter
Jun 4, 2026
EFFECT
Form EFFECT - Notice of Effectiveness
Nov 25, 2024
CORRESP
Form CORRESP - Correspondence
Nov 20, 2024
LETTER
Form UPLOAD - SEC-generated letter
Nov 19, 2024
